Vähähiilisen puurakentamisen aluetaloudelliset vaikutukset Kymenlaaksossa ja Kouvolassa

Tutkimuksessa vertailtiin kolmea päiväkodin rakentamistapaa. Ensimmäisessä materiaalina käytetään mahdollisimman paljon puuta. Toisessa käytetään puun lisäksi soveltuvin osin myös betonia. Kolmas vaihtoehto on moduuleina toteutettava päiväkoti, joka vietäisiin Uudellemaalle ja rakennettaisiin sinne Kouvolan seutukunnan työvoimaa käyttäen. Tulosten mukaan kaikki tutkitut päiväkodin rakennustavat tukevat Kymenlaakson maakunnan ja Kouvolan seutukunnan elintason, työllisyyden, palkkojen ja työtulojen kasvua. Rakentamisen aikana syntyy uusia työpaikkoja useille rakentamisen alihankintaketjun toimialoille. Uusien työpaikkojen määrä on korkein moduulivaihtoehdossa (8,0). Seuraavana on puusta rakentaminen, joka tuo 6,8 uutta työpaikkaa. Betonivaihtoehto tuo vähiten 5,8, uutta työpaikkaa. Tutkimuksen johtopäätös on, että päiväkodin rakentaminen on aluetalouden kannalta myönteinen asia elintasolla ja työllisyydellä mitattuna. Päiväkodin rakentaminen käyttäen mahdollisimman paljon paikallisia puumateriaaleja toisi yhden työpaikan enemmän kuin jos käytettäisiin puun lisäksi soveltuvin osin betonia

Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, A Novel Potential Therapeutic for the Treatment of Breast Cancer

Numerous lines of evidence suggest that the polypeptide hormone prolactin (PRL) may contribute to breast and prostate tumorigenesis through its interactions with the prolactin receptor (PRLR). Here we describe the biological properties of LFA102, a humanized neutralizing monoclonal antibody directed against the extracellular domain of PRLR. This antibody was found to effectively antagonize PRL-induced signaling in breast cancer cells in vitro and in vivo and to block PRL-induced proliferation in numerous cell line models, including examples of autocrine/paracrine PRL activity. A single administration of LFA102 resulted in regression of PRL-dependent Nb2-11 tumor xenografts and significantly prolonged time to progression. Finally, LFA102 treatment significantly inhibited PRLR signaling as well as tumor growth in a carcinogen-induced, estrogen receptor (ER)-positive rat mammary cancer model as a monotherapy and enhanced the efficacy of the aromatase inhibitor letrozole when administered in combination. The biological properties of LFA102, elucidated by the preclinical studies presented here, suggest that this antibody has the potential to be a first in class, effective therapeutic for the treatment of PRL-dependent cancers

Discovery of A Selective and Potent Inhibitor of MNK Kinase 1/2 Utilizing Structure-Based Drug Design

The discovery of a highly potent and selective small molecule inhibitor 8 for in vitro target validation of MNK1/2 kinases is described. The aminopyrazine benzimidazole series was derived from an HTS hit and optimized by utilization of a docking model, conformation analysis, and binding pocket comparison against anti-targets

Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design

The discovery of a highly potent and selective small molecule inhibitor <b>9</b> for in vitro target validation of MNK1/2 kinases is described. The aminopyrazine benzimidazole series was derived from an HTS hit and optimized by utilization of a docking model, conformation analysis, and binding pocket comparison against antitargets

Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design

The discovery of a highly potent and selective small molecule inhibitor <b>9</b> for in vitro target validation of MNK1/2 kinases is described. The aminopyrazine benzimidazole series was derived from an HTS hit and optimized by utilization of a docking model, conformation analysis, and binding pocket comparison against antitargets